help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yang, Q.
Right arrow Articles by Kakudo, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yang, Q.
Right arrow Articles by Kakudo, K.
(American Journal of Pathology. 2001;158:299-303.)
© 2001 American Society for Investigative Pathology


Regular Articles

Biallelic Inactivation of Retinoic Acid Receptor ß2 Gene by Epigenetic Change in Breast Cancer

Qifeng Yang*{dagger}, Ichiro Mori*, Liang Shan*{ddagger}, Misa Nakamura*, Yasushi Nakamura*, Hirotoshi Utsunomiya*, Goro Yoshimura{dagger}, Takaomi Suzuma{dagger}, Takeshi Tamaki{dagger}, Teiji Umemura{dagger}, Takeo Sakurai{dagger} and Kennichi Kakudo*

From the Second Department of Pathology*
and Department of Surgery,{dagger}
Wakayama Medical College, Wakayama, Japan; and the Laboratory of Experimental Carcinogenesis,{ddagger}
National Cancer Institute, Bethesda, Maryland

A growing body of evidence supports the hypotheses that retinoic acid receptor ß2 (RAR ß2) is a tumor suppressor gene. Although the loss of RAR ß2 expression has been reported in many malignant tumors, including breast cancer, the molecular mechanism is still poorly understood. We hypothesized that loss of RAR ß2 activity could result from multiple factors, including epigenetic modification and loss of heterozygosity (LOH). Using methylation-specific polymerase chain reaction and LOH analysis, we found that biallelic inactivation via epigenetic changes of both maternal and paternal alleles, or epigenetic modification of one allele combined with genetic loss of the remaining allele, could completely suppress RAR ß2 expression in breast cancer. Thus, it is possible that substantial numbers of human cancers arise through suppressor gene silencing via epigenetic mechanisms that inactivate both alleles. Because of this, chromatin-remodeling drugs may provide a novel strategy for cancer prevention and treatment.





This article has been cited by other articles:


Home page
JCOHome page
M. O. Hoque, O. Topaloglu, S. Begum, R. Henrique, E. Rosenbaum, W. Van Criekinge, W. H. Westra, and D. Sidransky
Quantitative Methylation-Specific Polymerase Chain Reaction Gene Patterns in Urine Sediment Distinguish Prostate Cancer Patients From Control Subjects
J. Clin. Oncol., September 20, 2005; 23(27): 6569 - 6575.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
N. P. Mongan and L. J. Gudas
Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RAR{beta}2 in breast cancer cells
Mol. Cancer Ther., March 1, 2005; 4(3): 477 - 486.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
C Jeronimo, R Henrique, J Oliveira, F Lobo, I Pais, M R Teixeira, and C Lopes
Aberrant cellular retinol binding protein 1 (CRBP1) gene expression and promoter methylation in prostate cancer
J. Clin. Pathol., August 1, 2004; 57(8): 872 - 876.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Kuroki, F. Trapasso, S. Yendamuri, A. Matsuyama, H. Alder, N. N. Williams, L. R. Kaiser, and C. M. Croce
Allelic Loss on Chromosome 3p21.3 and Promoter Hypermethylation of Semaphorin 3B in Non-Small Cell Lung Cancer
Cancer Res., June 15, 2003; 63(12): 3352 - 3355.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
L. Cordain, S. Lindeberg, M. Hurtado, K. Hill, S. B. Eaton, and J. Brand-Miller
Acne Vulgaris: A Disease of Western Civilization
Arch Dermatol, December 1, 2002; 138(12): 1584 - 1590.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. I. Chen, K. M. Sommer, and K. Swisshelm
Downstream Codons in the Retinoic Acid Receptor beta -2 and beta -4 mRNAs Initiate Translation of a Protein Isoform That Disrupts Retinoid-activated Transcription
J. Biol. Chem., September 13, 2002; 277(38): 35411 - 35421.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q. Yang, M. Nakamura, Y. Nakamura, G. Yoshimura, T. Suzuma, T. Umemura, Y. Shimizu, I. Mori, T. Sakurai, and K. Kakudo
Two-Hit Inactivation of FHIT by Loss of Heterozygosity and Hypermethylation in Breast Cancer
Clin. Cancer Res., September 1, 2002; 8(9): 2890 - 2893.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. Kwong, K.-W. Lo, K.-F. To, P. M. L. Teo, P. J. Johnson, and D. P. Huang
Promoter Hypermethylation of Multiple Genes in Nasopharyngeal Carcinoma
Clin. Cancer Res., January 1, 2002; 8(1): 131 - 137.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Q. Yang, G. Yoshimura, T. Suzuma, T. Tamaki, T. Umemura, M. Nakamura, Y. Nakamura, X. Wang, I. Mori, T. Sakurai, et al.
Clinicopathological Significance of Fragile Histidine Triad Transcription Protein Expression in Breast Carcinoma
Clin. Cancer Res., December 1, 2001; 7(12): 3869 - 3873.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Society for Investigative Pathology.